Literature DB >> 22348593

Modified-orientation log to assess hepatic encephalopathy.

M Salam1, S Matherly, I S Farooq, R T Stravitz, R K Sterling, A J Sanyal, D P Gibson, J B Wade, L R Thacker, D M Heuman, M Fuchs, P Puri, V Luketic, S J Bickston, J S Bajaj.   

Abstract

BACKGROUND: The subjectivity of the West-Haven criteria (WHC) hinders hepatic encephalopathy (HE) evaluation. The new HE classification has emphasised assessment of orientation. The modified-orientation log (MO-log, eight questions, scores 0-24; 24 normal) is adapted from a validated brain injury measure. AIM: To validate MO-log for HE assessment in cirrhosis.
METHODS: Cirrhotics admitted with/without HE were administered MO-log. We collected cirrhosis/HE details, admission/daily MO-logs and WHC (performed by different examiners), time to reach normal mentation (MO-log ≥23) and MO-log/WHC change (Δ) over day 1. Outcomes were in-hospital mortality, duration to normal mentation and length-of-stay (LOS). Regressions were performed for each outcome. MO-log inter-rater reliability was measured.
RESULTS: Ninety-six HE (55 ± 8 years, MELD 21) and 20 non-HE (54 ± 5 years, MELD 19) in-patients were included. In HE patients, median admission WHC was 3 (range 1-4). Mean MO-log was 12 ± 8 (range 0-22). Their LOS was 6 ± 5 days and 13% died. Time to reach normal mentation was 2.4 ± 1.7 days. Concurrent validity: there was a significant negative correlation between admission MO-log and WHC (r = -0.79, P < 0.0001). Discriminant validity: admission MO-logs were significantly lower in those who died (7 vs. 12, P = 0.03) and higher in those admitted without HE (23.6 vs. 12, P < 0.0001). MO-log improved in 69% on day 1 (ΔMO-log 4 ± 8) which was associated with lower duration to normal mentation (2 vs. 3.5 days, P = 0.03) and mortality (3% vs.43%, P < 0.0001), not ΔWHC. Regression models for all outcomes included admission/ΔMO-log but not WHC as a predictor. Inter-rater reliability: ICC for MO-log inter-rater observations was 0.991.
CONCLUSIONS: Modified-orientation log is a valid tool for assessing severity and is better than West-Haven criteria in predicting outcomes in hospitalised hepatic encephalopathy patients.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22348593      PMCID: PMC3616137          DOI: 10.1111/j.1365-2036.2012.05038.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Cognitive orientation in rehabilitation and neuropsychological outcome after traumatic brain injury.

Authors:  R N Dowler; B A Bush; T A Novack; W T Jackson
Journal:  Brain Inj       Date:  2000-02       Impact factor: 2.311

Review 2.  New assessment of hepatic encephalopathy.

Authors:  Juan Córdoba
Journal:  J Hepatol       Date:  2010-12-05       Impact factor: 25.083

Review 3.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

4.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

5.  Effective serial measurement of cognitive orientation in rehabilitation: the Orientation Log.

Authors:  W T Jackson; T A Novack; R N Dowler
Journal:  Arch Phys Med Rehabil       Date:  1998-06       Impact factor: 3.966

6.  Assessment of coma and impaired consciousness. A practical scale.

Authors:  G Teasdale; B Jennett
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

7.  Hepatic Encephalopathy.

Authors:  A T Blei; J Córdoba
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

8.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

9.  Development of a clinical hepatic encephalopathy staging scale.

Authors:  M Ortiz; J Córdoba; E Doval; C Jacas; F Pujadas; R Esteban; J Guardia
Journal:  Aliment Pharmacol Ther       Date:  2007-09-15       Impact factor: 8.171

10.  Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA).

Authors:  Tarek I Hassanein; Robin C Hilsabeck; William Perry
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

View more
  6 in total

1.  Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Authors:  J S Bajaj; R T Frederick; N M Bass; M Ghabril; K Coyne; M K Margolis; M Santoro; D F Coakley; M Mokhtarani; M Jurek; B F Scharschmidt
Journal:  Metab Brain Dis       Date:  2016-06-09       Impact factor: 3.584

2.  The confusion assessment method for the intensive care unit in patients with cirrhosis.

Authors:  Eric S Orman; Anthony Perkins; Marwan Ghabril; Babar A Khan; Naga Chalasani; Malaz A Boustani
Journal:  Metab Brain Dis       Date:  2015-05-07       Impact factor: 3.584

Review 3.  Useful tests for hepatic encephalopathy in clinical practice.

Authors:  Eiman Nabi; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2014-01

4.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

5.  Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.

Authors:  Vishwadeep Ahluwalia; Douglas M Heuman; George Feldman; James B Wade; Leroy R Thacker; Edith Gavis; HoChong Gilles; Ariel Unser; Melanie B White; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2014-08-08       Impact factor: 25.083

6.  Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study.

Authors:  Ashley Bloom; Vanessa Weerasinghe Mudiyansalage; Anna Rhodes; Malcolm Hogg; Chatura Jayasekera; Alexandra Gorelik; Siddharth Sood; Amanda Nicoll
Journal:  Clin Exp Hepatol       Date:  2020-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.